A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma.


Journal

Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829

Informations de publication

Date de publication:
02 2019
Historique:
received: 19 11 2017
accepted: 02 04 2018
pubmed: 22 4 2018
medline: 2 9 2020
entrez: 22 4 2018
Statut: ppublish

Résumé

Resident and peripherally derived glioma associated microglia/macrophages (GAMM) play a key role in driving tumour progression, angiogenesis, invasion and attenuating host immune responses. Differentiating these cells' origins is challenging and current preclinical models such as irradiation-based adoptive transfer, parabiosis and transgenic mice have limitations. We aimed to develop a novel nonmyeloablative transplantation (NMT) mouse model that permits high levels of peripheral chimerism without blood-brain barrier (BBB) damage or brain infiltration prior to tumour implantation. NMT dosing was determined in C57BL/6J or Pep3/CD45.1 mice conditioned with concentrations of busulfan ranging from 25 mg/kg to 125 mg/kg. Donor haematopoietic cells labelled with eGFP or CD45.2 were injected via tail vein. Donor chimerism was measured in peripheral blood, bone marrow and spleen using flow cytometry. BBB integrity was assessed with anti-IgG and anti-fibrinogen antibodies. Immunocompetent chimerised animals were orthotopically implanted with murine glioma GL-261 cells. Central and peripheral cell contributions were assessed using immunohistochemistry and flow cytometry. GAMM subpopulation analysis of peripheral cells was performed using Ly6C/MHCII/MerTK/CD64. NMT achieves >80% haematopoietic chimerism by 12 weeks without BBB damage and normal life span. Bone marrow derived cells (BMDC) and peripheral macrophages accounted for approximately 45% of the GAMM population in GL-261 implanted tumours. Existing markers such as CD45 high/low proved inaccurate to determine central and peripheral populations while Ly6C/MHCII/MerTK/CD64 reliably differentiated GAMM subpopulations in chimerised and unchimerised mice. NMT is a powerful method for dissecting tumour microglia and macrophage subpopulations and can guide further investigation of BMDC subsets in glioma and neuro-inflammatory diseases.

Identifiants

pubmed: 29679380
doi: 10.1111/nan.12489
pmc: PMC7379954
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-140

Informations de copyright

© 2018 The Authors Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Références

Cancer Immunol Immunother. 2011 Feb;60(2):153-60
pubmed: 21120655
Mol Ther. 2013 Apr;21(4):868-76
pubmed: 23423338
Brain. 2007 Feb;130(Pt 2):476-89
pubmed: 17107968
J Cell Mol Med. 2010 Jul;14(7):1946-52
pubmed: 19765171
Immunotherapy. 2014;6(6):663-6
pubmed: 25041027
Oncogene. 2008 Feb 7;27(7):918-30
pubmed: 17684491
Neurosurgery. 2000 Apr;46(4):957-61; discussion 961-2
pubmed: 10764271
Exp Hematol. 2003 Dec;31(12):1348-56
pubmed: 14662344
PLoS One. 2015 Feb 06;10(2):e0116644
pubmed: 25658639
Neuropathol Appl Neurobiol. 2019 Feb;45(2):119-140
pubmed: 29679380
J Pharmacol Exp Ther. 2006 Nov;319(2):551-60
pubmed: 16882877
Mol Ther. 2012 Aug;20(8):1610-21
pubmed: 22547151
Neuroreport. 2003 Mar 24;14(4):629-31
pubmed: 12657900
Cancer Res. 2014 Jul 15;74(14):3727-39
pubmed: 24820020
Neuro Oncol. 2010 Nov;12(11):1113-25
pubmed: 20667896
Cytokine. 2013 Oct;64(1):131-7
pubmed: 23962752
Nat Immunol. 2014 Oct;15(10):929-937
pubmed: 25151491
J Immunol. 1995 May 1;154(9):4309-21
pubmed: 7722289
Transplantation. 1993 Jul;56(1):185-90
pubmed: 8101401
Cell Immunol. 2014 Sep-Oct;291(1-2):41-8
pubmed: 24726741
Glia. 2011 Aug;59(8):1169-80
pubmed: 21446047
Lancet. 2009 Sep 12;374(9693):856-8
pubmed: 19729197
J Neurosci. 2010 Jul 28;30(30):10086-95
pubmed: 20668193
J Neurosurg. 2009 Mar;110(3):572-82
pubmed: 19199469
BMC Cancer. 2016 Feb 08;16:72
pubmed: 26856327
Annu Rev Immunol. 2009;27:119-45
pubmed: 19302036
Acta Neuropathol. 2014 Sep;128(3):347-62
pubmed: 24722970
Int J Cancer. 2015 Jul 15;137(2):278-88
pubmed: 25477239
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
PLoS One. 2014 Sep 23;9(9):e107649
pubmed: 25247590
Glia. 2011 Mar;59(3):472-85
pubmed: 21264953
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nat Immunol. 2012 Nov;13(11):1118-28
pubmed: 23023392
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Clin Dev Immunol. 2013;2013:285246
pubmed: 23983766
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Immunity. 2013 Sep 19;39(3):599-610
pubmed: 24012416
Science. 2001 Nov 30;294(5548):1933-6
pubmed: 11729320
J Oncol Pract. 2017 Oct;13(10):629-638
pubmed: 29020535
PLoS One. 2013;8(3):e58544
pubmed: 23526995
Nat Neurosci. 2007 Dec;10(12):1538-43
pubmed: 18026097
JCI Insight. 2016;1(2):
pubmed: 26973881
Blood. 2003 Jun 1;101(11):4305-12
pubmed: 12576326
Eur J Immunol. 2012 Dec;42(12):3150-66
pubmed: 22936024
Mol Ther. 2013 Oct;21(10):1938-49
pubmed: 23748415
Bioinformatics. 2011 Apr 15;27(8):1179-80
pubmed: 21349861
Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206
pubmed: 28767130
Cell Transplant. 2012;21(6):1149-59
pubmed: 21944997
Cancer Res. 2010 Jun 15;70(12):4829-39
pubmed: 20501837
Cancer Sci. 2006 Jun;97(6):546-53
pubmed: 16734735
Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7438-42
pubmed: 1651506
Acta Neuropathol. 2016 Mar;131(3):365-78
pubmed: 26718201
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46
pubmed: 26884166
Methods Mol Biol. 2014;1135:275-88
pubmed: 24510872
Cell Rep. 2016 Nov 22;17(9):2445-2459
pubmed: 27840052
Genome Res. 2000 Nov;10(11):1788-95
pubmed: 11076863
Cancer Sci. 2012 Dec;103(12):2165-72
pubmed: 22957741
J Transl Med. 2014 Apr 29;12:107
pubmed: 24779345
PLoS One. 2013 Nov 07;8(11):e80260
pubmed: 24244666
Acta Neuropathol. 2017 Feb;133(2):263-282
pubmed: 28074274
Brain. 2017 Jun 1;140(6):1548-1560
pubmed: 28334886
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Neuro Oncol. 2012 Aug;14(8):958-78
pubmed: 22573310
Glia. 2016 Jul;64(7):1210-26
pubmed: 27143298
Dis Model Mech. 2013 Jul;6(4):1043-8
pubmed: 23519030

Auteurs

K Yu (K)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Department of Neurosurgery, Salford Royal Hospital, Salford, UK.

A S Youshani (AS)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Department of Neurosurgery, Salford Royal Hospital, Salford, UK.

F L Wilkinson (FL)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Centre for Bioscience, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.

C O'Leary (C)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

P Cook (P)

Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UK.

L Laaniste (L)

Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.

A Liao (A)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

D Mosses (D)

Department of Neurosurgery, Royal Manchester Children's Hospital, Manchester, UK.

C Waugh (C)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

H Shorrock (H)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

O Pathmanaban (O)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Department of Neurosurgery, Salford Royal Hospital, Salford, UK.

A Macdonald (A)

Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UK.

I Kamaly-Asl (I)

Department of Neurosurgery, Royal Manchester Children's Hospital, Manchester, UK.

F Roncaroli (F)

Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

B W Bigger (BW)

Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH